Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.56 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GLB1 | P16278 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928798 | 0.88 | KDM1A (0.47) | GBA1KDM1AMAOABACE1MAOB | |
| SCHEMBL17172483 | 0.88 | KDM1A (0.47) | GBA1KDM1AMAOABACE1MAOB | |
| SCHEMBL348725 | 0.88 | KDM1A (0.47) | GBA1KDM1AMAOABACE1MAOB | |
| SCHEMBL3926813 | 0.88 | KDM1A (0.47) | GBA1KDM1AMAOABACE1MAOB | |
| SCHEMBL3870077 | 0.80 | MAOA (0.55) | KDM1AMAOABACE1MAOBCCR5 | |
| SCHEMBL3870080 | 0.80 | MAOA (0.55) | KDM1AMAOABACE1MAOBCCR5 | |
| SCHEMBL8660684 | 0.80 | MAOA (0.55) | KDM1AMAOABACE1MAOBCCR5 | |
| SCHEMBL8870050 | 0.74 | KDM1A (0.50) | KDM1AMAOAMAOB | |
| SCHEMBL8471748 | 0.74 | KDM1A (0.50) | KDM1AMAOAMAOB | |
| SCHEMBL11565325 | 0.74 | KDM1A (0.50) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | claimed |
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| US-20050054618-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | RYTVED KLAUS ASGER (DK) | 2005-03-10 | — | — | US | disclosed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | disclosed |
| US-5863903-A | ANTIDIABETIC AGENT | NOVO NORDISK A/S (DK) | 1999-01-26 | — | — | US | disclosed |
| WO-1995024391-A1 | PIPERIDINES AND PYRROLIDINES | NOVO NORDISK A/S (DK) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054618-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 308/4885FUCA1 957/4885GLA 170/4885 |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 308/4885FUCA1 957/4885GLA 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.